OneMedNet Corporation

https://www.onemednet.com

OneMedNet Corporation is a leading provider and curator of regulatory-grade Real-World Data (RWD), primarily focusing on imaging RWD, through its proprietary iRWD™ platform. The company's mission is to revolutionize how RWD is accessed and utilized, thereby fueling breakthroughs for drugmakers, medical device pioneers, and AI innovators. Headquartered in Eden Prairie, Minnesota, OneMedNet aims to positively impact patient lives and enhance customer productivity by accelerating the development and market entry of safer and more effective patient care solutions.

The company's core offering, the iRWD™ platform, securely de-identifies, searches, and curates diverse clinical data, including medical imaging, electronic health records (EHR), laboratory results, and pathology reports, from an extensive federated network of healthcare providers. OneMedNet provides both customized data packages and pre-packaged imaging RWD sets to meet the rigorous demands of life science research and AI development. Beyond healthcare, the company also applies its proprietary AI to anonymize data for other sectors such as finance, retail, and telecom, enabling secure data sharing and system optimization.

OneMedNet has demonstrated strong financial performance, reporting a 329% year-over-year increase in RWD revenue in 2025. Recent notable developments include strategic collaborations with companies like Navidence, Onco-Innovations, Inka Health, and Medcase, aimed at enhancing data analytics, accelerating oncology drug development, and expanding into the healthcare data annotation market. The company has also integrated AI into its data curation processes, significantly boosting efficiency and speed in delivering de-identified datasets. With Aaron Green serving as President and CEO, and Dr. Jeffrey Yu as Chairman and Chief Medical Officer, OneMedNet continues to expand its network, which encompasses over 2,130 healthcare sites, positioning itself as a key player in redefining patient care and driving innovation in the healthcare data landscape.

Latest updates

OneMedNet Integrates Palantir Foundry, Bolsters Real-World Data Network

Event summary

  • OneMedNet’s iRWD™ Platform, built on Palantir Foundry, is now live, providing searchable access to billions of records across 80 million patient journeys.
  • The network has grown ~70% to 80 million patients and 251 million studies.
  • The platform provides access to approximately 47 million tokenized patients via Datavant.
  • Two new customers have contracted for the iRWD™ Platform.

The big picture

OneMedNet’s integration of Palantir Foundry and Datavant represents a significant push in the burgeoning real-world data market, which is increasingly vital for AI model development and drug discovery. The company’s strategy of combining curated data with tokenized patient linkage aims to create a durable competitive advantage, but the success hinges on converting interest into consistent, high-margin subscriptions and navigating the complex regulatory landscape surrounding patient data.

What we're watching

Subscription Adoption
The ability to convert the growing customer pipeline into meaningful annual recurring revenue will be a key indicator of the platform’s success and OneMedNet’s overall financial performance.
Data Security
How OneMedNet manages the security and privacy of the vast, tokenized patient data pool will be critical to maintaining trust with customers and avoiding regulatory scrutiny.
Competitive Landscape
The emergence of other large-scale, AI-driven RWD platforms could erode OneMedNet’s competitive advantage and necessitate ongoing innovation to maintain market share.

OneMedNet Swings to Profitability, Rides Palantir Partnership

Event summary

  • OneMedNet revenue surged 329% year-over-year to $1.254 million in 2025, from $292,000 in 2024.
  • The company significantly reduced total liabilities by 74%, decreasing from $19.7 million to $5.1 million, through settlements and debt-to-equity conversions.
  • Shareholder deficit was substantially reduced from $(16.0) million to $(3.0) million.
  • OneMedNet is piloting its AI-driven iRWD™ platform with two customers, anticipating four more in 2026, each with a seven-figure subscription potential.
  • The company sunset its BEAM solution, eliminating associated expenses and focusing on its Real-World Data business.

The big picture

OneMedNet's turnaround, marked by substantial revenue growth and a dramatically improved balance sheet, signals a potential shift in the Real-World Data landscape. The partnership with Palantir Foundry positions the company to capitalize on the increasing demand for AI-powered data analytics in healthcare, but also introduces a key dependency. The company's transition to a subscription-based model is a positive sign, but hinges on consistent customer acquisition and retention.

What we're watching

Execution Risk
The ability to onboard the anticipated four additional customers in 2026, each representing a seven-figure subscription, will be critical to sustaining the current growth trajectory and validating the platform's commercial appeal.
Palantir Dependency
OneMedNet’s reliance on Palantir Foundry introduces a dependency risk; changes in Palantir’s pricing, technology, or strategic direction could materially impact OneMedNet’s platform and competitive advantage.
Scalability
The projected 4x platform growth by the end of 2026 requires significant operational scaling, and whether OneMedNet can manage this expansion without compromising data quality or customer service remains to be seen.

OneMedNet Secures Oncology Data Deal, Bolsters AI Platform

Event summary

  • OneMedNet has entered a collaboration with Onco-Innovations and its subsidiary, Inka Health, granting Inka Health access to OneMedNet’s iRWD™ platform.
  • The agreement focuses on utilizing real-world data and AI to accelerate development of Onco-Innovations’ PNKP Inhibitor Technology for PTEN/SHP1-deficient cancers.
  • Inka Health intends to integrate OneMedNet’s data into its SynoGraph™ AI platform for predicting cancer treatment success and safety.
  • The deal highlights the intended use of OneMedNet’s iRWD™ platform for identifying rare patient populations at scale.

The big picture

This collaboration underscores the increasing importance of real-world data and AI in accelerating oncology drug development, a trend driven by the need to reduce costs and timelines in a sector facing mounting pressure. OneMedNet’s partnership with Onco-Innovations validates its iRWD™ platform, which leverages Palantir’s Foundry, and positions it to capitalize on the growing demand for regulatory-grade data and AI-powered analytics within the pharmaceutical industry. The deal also highlights the trend of smaller biotech firms leveraging established data platforms to augment their research and development capabilities.

What we're watching

Platform Adoption
The success of this collaboration hinges on Inka Health’s ability to effectively integrate OneMedNet’s iRWD™ platform into its existing workflows and demonstrate tangible benefits for drug development.
Regulatory Scrutiny
Increased reliance on real-world data in oncology drug development will likely draw greater regulatory scrutiny regarding data quality, bias mitigation, and validation of AI-driven insights.
Competitive Landscape
The growing demand for real-world data and AI solutions in oncology will intensify competition among platforms like OneMedNet’s iRWD™ and others, potentially impacting pricing and market share.

OneMedNet Integrates Navidence's CODefs to Expedite Real-World Data Analysis

Event summary

  • OneMedNet and Navidence have formed a strategic collaboration to integrate Navidence’s Computable Operational Definitions (CODefs) with OneMedNet’s iRWD™ platform.
  • The collaboration aims to streamline real-world data analysis for pharmaceutical companies, accelerating study design and reducing data procurement costs.
  • Navidence’s CODefs standardize data queries across datasets, while OneMedNet provides a large-scale multimodal data infrastructure.
  • The Real-World Data market is projected to grow from $1.88 billion in 2025 to $6.37 billion by 2034, exhibiting a 14.54% CAGR.

The big picture

The collaboration reflects the growing pressure on pharmaceutical companies to leverage real-world data for regulatory approvals and AI model training. Standardizing data analysis through CODefs addresses a key bottleneck in the RWD workflow, potentially accelerating drug development timelines and reducing costs. This partnership positions both companies to capitalize on the expanding RWD market, but also intensifies competition in a rapidly evolving space.

What we're watching

Execution Risk
The success of this collaboration hinges on the seamless integration of Navidence’s CODefs with OneMedNet’s iRWD™ platform, and the ability to demonstrate tangible efficiency gains for customers.
Regulatory Scrutiny
Increased reliance on real-world evidence will likely draw greater scrutiny from regulatory bodies like the FDA and EMA, requiring OneMedNet to maintain robust data governance and validation processes.
Competitive Landscape
The RWD market is becoming increasingly crowded; OneMedNet must differentiate its offering beyond standardized definitions to retain and attract customers.

OneMedNet Converts Evaluations to Subscriptions, Bolsters Recurring Revenue

Event summary

  • OneMedNet is actively converting customer evaluations of its RWD platform, powered by Palantir Foundry, into commercial subscriptions.
  • The company demonstrated its platform’s capabilities at tradeshows in November 2025, showcasing live feeds, subscription access, and AI-driven search.
  • OneMedNet’s iRWD network now encompasses over 2,130 healthcare sites.
  • Early subscription contracts include multi-year deals representing millions in incremental recurring revenue.

The big picture

OneMedNet's commercial launch represents a significant step in the burgeoning real-world data market, which is increasingly vital for drug development, clinical trial optimization, and personalized medicine. The company’s reliance on Palantir Foundry highlights the growing trend of specialized data platforms being integrated with broader analytics infrastructure. The multi-year subscription deals suggest a growing confidence in the value of RWD, but also introduce a longer sales cycle and potential churn risk.

What we're watching

Conversion Rate
The sustainability of OneMedNet’s growth hinges on its ability to maintain a high conversion rate from evaluations to paid subscriptions, particularly given the multi-year commitment required.
Network Scale
Further expansion of the iRWD network beyond 2,130 sites will be critical to sustaining the upward trajectory of subscription value and attracting larger clients.
Palantir Dependency
OneMedNet's reliance on Palantir Foundry introduces a potential point of vulnerability; the company’s performance is intrinsically linked to Palantir’s continued investment and support of the platform.

OneMedNet Bolsters Autoimmune Data Assets via ViuHealth Partnership

Event summary

  • OneMedNet has partnered with ViuHealth to expand its autoimmune clinical ontology and data scale.
  • The agreement integrates ViuHealth’s longitudinal autoimmune disease data into OneMedNet’s iRWD™ platform.
  • The partnership is intended to accelerate OneMedNet’s recurring revenue strategy, particularly within the $166+ billion autoimmune therapeutics market.
  • OneMedNet’s bookings grew 815% YoY and inbound demand increased 4.5X in the prior quarter (November 17, 2025).

The big picture

OneMedNet is strategically positioning itself as a critical infrastructure provider within the rapidly expanding real-world data market, specifically targeting high-value specialty areas like autoimmune diseases. This partnership underscores the shift towards subscription-based data models, moving away from transactional data sales and creating a more predictable revenue stream. The $166+ billion autoimmune therapeutics market represents a significant growth opportunity, but also a highly competitive landscape where data quality and insights are paramount.

What we're watching

Subscription Retention
The success of this partnership hinges on OneMedNet’s ability to retain ViuHealth’s data and convert it into long-term subscription revenue, rather than a one-time data purchase.
Data Quality
The value of OneMedNet’s offering is directly tied to the quality and longitudinal depth of the data acquired from ViuHealth; any degradation in data quality could undermine the platform’s appeal.
Foundry Dependency
OneMedNet’s reliance on Palantir Foundry introduces a potential dependency risk; changes in Palantir’s pricing or platform capabilities could significantly impact OneMedNet’s margins and operational flexibility.

OneMedNet Secures Neuro Data Deal, Bolsters AI-Driven RWD Offering

Event summary

  • OneMedNet has entered a multi-year data licensing agreement with Risorius, a neurotechnology company.
  • The agreement involves Risorius licensing access to OneMedNet’s EEG and PSG waveform data, paired with clinical context.
  • The deal is expected to generate millions of dollars in incremental recurring revenue for OneMedNet.
  • Risorius selected OneMedNet based on data quality, volume, and a practical licensing approach.
  • The agreement was executed rapidly, highlighting commercial alignment and perceived value.

The big picture

The partnership reflects a broader trend of AI-native companies leveraging real-world data to develop digital biomarkers and accelerate CNS drug development. OneMedNet’s ability to secure this deal positions it as a key infrastructure provider within a rapidly growing market, but also highlights the increasing importance of regulatory-grade data in the AI-driven healthcare landscape. The deal's rapid closure suggests OneMedNet’s data assets and delivery model are increasingly attractive to specialized research firms.

What we're watching

Execution Risk
The rapid execution of this deal suggests strong alignment, but OneMedNet must ensure it can consistently deliver the promised data volume and quality to maintain Risorius’s satisfaction and avoid churn.
Competitive Landscape
The deal underscores the growing demand for neuro-focused RWD, and OneMedNet will face increasing competition from other data providers seeking to capitalize on this trend.
Expansion Potential
Risorius’s stated intention to expand its database and R&D projects suggests potential for further data licensing agreements with OneMedNet, but hinges on the initial project’s success.

OneMedNet Bookings Surge 4x, Signals Shift to Subscription Model

Event summary

  • OneMedNet reported $2.79 million in bookings for 2025, a 4.1x increase compared to $684,000 in 2024.
  • The company attributes the booking growth to larger deal sizes and increased enterprise demand for AI-powered Real-World Data (RWD).
  • OneMedNet is actively transitioning from project-based engagements to a recurring subscription model, evidenced by agreements with Circle CVI and mlHealth360.
  • New product offerings include Subscription Search (powered by Palantir Foundry) and Subscription Data License, priced higher than traditional data projects.

The big picture

OneMedNet's accelerated booking growth and strategic shift towards a subscription model reflect a broader trend in the healthcare data space, where real-world data is increasingly critical for AI model development and regulatory approvals. The company’s reliance on Palantir Foundry to deliver these subscription services positions it within a growing market for enterprise AI platforms, but also introduces a dependency risk. The success of this transition will be a key indicator of OneMedNet’s ability to capitalize on the increasing demand for RWD and establish a durable, recurring revenue stream.

What we're watching

ARR Trajectory
The sustainability of the ARR growth hinges on OneMedNet’s ability to convert existing data project clients to subscription agreements and expand within those accounts.
Palantir Dependency
OneMedNet’s reliance on Palantir Foundry for key product features introduces a potential risk if the partnership weakens or Palantir’s pricing structure changes.
Competitive Landscape
The success of OneMedNet’s premium subscription offerings will depend on its ability to differentiate its value proposition from competitors offering similar RWD and AI-powered analytics solutions.

OneMedNet Data Fuels FDA Clearance, Validating RWD Market

Event summary

  • OneMedNet’s real-world data supported mlHealth 360’s FDA 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software for intracranial hemorrhage detection.
  • Scaida BrainCT-ICH analyzes head CT scans in approximately 5.97 seconds.
  • The clearance validates OneMedNet’s position as a provider of regulatory-grade real-world data.
  • OneMedNet’s iRWD™ platform spans over 2,130 healthcare sites.

The big picture

The FDA clearance of Scaida BrainCT-ICH, enabled by OneMedNet’s data, underscores the growing importance of real-world data in accelerating the development and regulatory approval of AI-powered medical solutions. This validates the emerging market for RWD providers, but also highlights the increasing scrutiny around data quality and regulatory compliance within the healthcare AI space. OneMedNet’s success is tied to its ability to scale its data platform and maintain its reputation as a trusted partner for regulated AI innovation.

What we're watching

Customer Concentration
The reliance on a single partner, mlHealth 360, for this validation creates a potential concentration risk for OneMedNet; future success hinges on expanding its client base and demonstrating broader applicability of its data.
Regulatory Scrutiny
Increased FDA reliance on real-world data for AI clearance could lead to more stringent validation requirements and potentially impact OneMedNet's ability to support future submissions.
Data Quality
Maintaining the high quality and regulatory compliance of OneMedNet’s data will be crucial to sustaining its competitive advantage and attracting new clients in a rapidly evolving market.

OneMedNet Secures Validation Deal, Signals Subscription Model Traction

Event summary

  • OneMedNet delivered a real-world data feed to an unnamed healthcare data and analytics organization.
  • The data feed comprises 1.5 million patients and 4 million encounters, totaling over 1.49 billion data points.
  • The delivery validated the recipient's platform's ability to ingest and harmonize complex healthcare data.
  • OneMedNet operates under a subscription model, transitioning customers to recurring revenue streams.

The big picture

OneMedNet's deal underscores the growing demand for regulatory-grade real-world data (RWD) within the life sciences sector, driven by the need for faster drug development and more personalized medicine. The shift to a subscription model represents a strategic move to build predictable revenue streams and foster long-term partnerships, a common trend among data providers seeking to move beyond transactional sales. This validation is a crucial step in demonstrating the viability of their platform and attracting further enterprise clients.

What we're watching

Customer Adoption
The success of OneMedNet's subscription model hinges on continued customer adoption and expansion of these large-scale data feeds, which will be a key indicator of future revenue growth.
Platform Scalability
The ability to consistently deliver and manage datasets of this size will test the scalability of OneMedNet’s iRWD platform and its reliance on Palantir AIP Foundry.
Competitive Landscape
Increased competition in the real-world data space could pressure OneMedNet’s pricing and margins, requiring ongoing differentiation through data quality and platform capabilities.

OneMedNet Shrinks Liabilities, Bets on Palantir AI for Data Access

Event summary

  • OneMedNet reduced total liabilities by approximately $19.6 million, a 75% reduction year-over-year.
  • The company integrated Palantir’s AI platform (AIP) to accelerate platform development and launch an AI-driven multimodal subscription search.
  • OneMedNet expanded its healthcare provider network by 37% year-over-year, reaching 186 million clinical exams across 2,130 sites.
  • Third quarter bookings increased eightfold year-over-year from 2024 to 2025.

The big picture

OneMedNet is positioning itself to capitalize on the growing demand for Real-World Data (RWD) driven by the rise of AI in healthcare and the increasing acceptance of RWE by regulators. The partnership with Palantir represents a significant bet on AI-powered data analytics, but also introduces a dependency on a key vendor. The company’s focus on subscription-based access models signals a shift away from traditional data licensing, aiming for more predictable and recurring revenue streams.

What we're watching

Execution Risk
The success of OneMedNet’s strategy hinges on the effective integration of Palantir’s AIP and the rapid adoption of its new AI-driven platform, which could face technical or market challenges.
Customer Retention
While repeat orders and MSAs are positive indicators, the company must demonstrate sustained customer loyalty and expansion within the life sciences and healthcare sectors to justify the investment in the platform.
Regulatory Shifts
The increasing reliance on Real-World Evidence (RWE) by regulatory bodies like the FDA and EMA creates both opportunity and risk, as changes in guidelines could impact OneMedNet’s business model and growth trajectory.
CID: 177